편두통 치료제 시장 규모, 점유율, 성장 분석 : 치료법별, 치료 분야별, 투여 경로별, 지역별 - 업계 예측(2026-2033년)

Migraine Drugs Market size was valued at USD 5.31 Billion in 2024 and is poised to grow from USD 6.27 Billion in 2025 to USD 23.55 Billion by 2033, growing at a CAGR of 18% during the forecast period (2026-2033).

The migraine drugs market is focused on medications designed to alleviate or prevent migraine symptoms, categorized into acute and preventive treatments. Acute medications address recent migraine attacks, while preventive options aim to reduce the frequency of severe episodes. The market is propelled by heightened awareness of effective preventive solutions, advancements in diagnostic capabilities, and the introduction of innovative therapies. However, growth is hindered by the high cost of new treatments and potential side effects, which can lead to hesitancy among healthcare providers and patients. Despite these challenges, the market is poised for significant growth, driven by advancements in drug development, a shift towards personalized medicine, and expanding opportunities in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Migraine Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Migraine Drugs Market Segments Analysis

Global Migraine Drugs Market is segmented by Treatment, Therapeutic Class, Route of Administration, Age Group, Availability and region. Based on Treatment, the market is segmented into Acute, Preventive. Based on Therapeutic Class, the market is segmented into CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Others. Based on Age Group, the market is segmented into Pediatric, Adult, Geriatric. Based on Availability, the market is segmented into Prescription Drugs, Over-the-Counter (OTC) Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Migraine Drugs Market

The Migraine Drugs market is significantly driven by the emergence of innovative drug classes such as CGRP gepants and inhibitors, which symbolize substantial advancements in migraine treatment. These new therapies employ precise mechanisms that have demonstrated their effectiveness in reducing both the intensity and occurrence of migraines, further stimulating market expansion. Additionally, ongoing research into the underlying causes of migraines is leading to the creation of advanced therapeutic options. Enhancements in understanding the genetic and molecular foundations of migraines are facilitating the rise of personalized treatments, setting the stage for a more tailored approach to managing this debilitating condition.

Restraints in the Migraine Drugs Market

The Migraine Drugs market faces significant challenges, as the efficacy of various treatments can vary widely among patients, leading to dissatisfaction and decreased acceptance of certain medications. This variability may prompt individuals to seek alternative therapies that they perceive as more effective. Additionally, some new treatments are associated with side effects that can hinder patients' quality of life, causing them to either stop using these medications or rely on additional drugs to manage adverse reactions. Such issues highlight the complexities within the market and underscore the need for more personalized approaches in migraine treatment.

Market Trends of the Migraine Drugs Market

The migraine drugs market is experiencing a significant shift toward CGRP inhibitors, which have rapidly emerged as a preferred choice for both patients and healthcare providers. These innovative treatments, exemplified by products such as Aimovig, Emgality, and Ajovy, demonstrate remarkable efficacy in reducing the frequency and intensity of migraines, leading to increased acceptance among chronic sufferers. The appeal of these medications lies in their personalized dosing regimen, allowing for monthly or quarterly administration that enhances patient compliance and quality of life. As awareness of migraine's debilitating impact grows, the demand for effective preventive treatments like CGRP inhibitors is expected to flourish.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Technological Advancement
• Regulatory Landscape
• Patent Analysis
• Value Chain Analysis
• Case Study Analysis
• PESTEL Analysis
• Macro-Economic Indicators
• Trade Analysis
• Market Attractiveness Index
• Supply Chain Analysis
• Pricing Analysis

Global Migraine Drugs Market Size by Treatment & CAGR (2026-2033)

• Acute
• Preventive

Global Migraine Drugs Market Size by Therapeutic Class & CAGR (2026-2033)

• CGRP monoclonal antibodies
• CGRP small molecule antagonists
• Acetylcholine inhibitors/ neurotoxins
• Triptans
• Ditans
• Ergot alkaloids
• NSAIDs
• Others

Global Migraine Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Oral
• Injectable
• Others

Global Migraine Drugs Market Size by Age Group & CAGR (2026-2033)

• Pediatric
• Adult
• Geriatric

Global Migraine Drugs Market Size by Availability & CAGR (2026-2033)

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

Global Migraine Drugs Market Size & CAGR (2026-2033)

• North America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • US
  • Canada
• Europe, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biohaven Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biohaven Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynerba Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation